Thus, these studies provided evidence that neuroencrine breast cancers display a profile of somatic mutations that appears to be different from common types of ER+/HER2- breast carcinomas and, to some extent, intermediate between luminal A and luminal B breast carcinomas from TCGA [252,253]. This evidence concerns the gene ERBB2 and breast cancer.